Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 12, 2026 · Charter amendment · Financial statements
GT Biopharma, Inc.
7
Charter amendment
Jun 12, 2026
| ItemItem | Disclosure |
|---|---|
| Item 5.03 | Amended articles of incorporation or bylaws |
| Item 9.01 | Financial statements and exhibits |
GT Biopharma, Inc. filed this 8-K to disclose: ) N/A 1 (Address of Principal Executive Offices and zip code) (415) 919-4040 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following prov…
The filing reports Items 5.03, 9.01. None of these codes are typically workforce-tagged, but analysts still review them for indirect labor-market signals.
GT Biopharma, Inc. filed this 8-K with the SEC. cutoffs links it to the employer's layoff history, visa filings, and other labor-market signals.
